TransMedics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Rhea-AI Summary

TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the results.

Investors can participate in the conference call by dialing (844) 481-2832 (domestic) or (412) 317-1852 (international). A live and archived webcast will be available on the company's investor relations website.

News Market Reaction – TMDX

+1.35%

+1.35% Session move

In the trading session that priced this news, TMDX gained 1.35%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ANDOVER, Mass., Feb. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (844) 481-2832 for domestic callers or (412) 317-1852 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.   

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-27-2025-302376124.html

SOURCE TransMedics Group, Inc.

FAQ

When will TransMedics (TMDX) release Q4 and full year 2024 earnings?

TransMedics will release its Q4 and full year 2024 financial results after market close on Thursday, February 27, 2025.

How can investors join the TransMedics (TMDX) Q4 2024 earnings call?

Investors can join by dialing (844) 481-2832 (domestic) or (412) 317-1852 (international) and asking to join the TransMedics call. A webcast will also be available on the company's investor relations website.

What time is the TransMedics (TMDX) Q4 2024 earnings conference call?

The earnings conference call will begin at 4:30 p.m. ET / 1:30 p.m. PT on February 27, 2025.

Where can I find the webcast for TransMedics (TMDX) Q4 2024 earnings call?

The live and archived webcast will be available on the 'Investors' section of the TransMedics website at https://investors.transmedics.com/.